viltolarsen (Rx)

Brand and Other Names:Viltepso
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injection, solution

  • 250mg/5mL (50mg/mL) single-dose vial

Duchenne Muscular Dystrophy

Indicated for Duchenne muscular dystrophy (DMD) in patients with a confirmed DMD gene mutation that is amenable to exon 53 skipping

80 mg/kg IV qWeek

Dosage Modifications

Renal impairment

  • Not studied
  • Excreted mostly unchanged in urine; therefore, renal impairment may increase viltolarsen exposure
  • Owing to the effect of reduced skeletal muscle mass on creatinine measurements in DMD, no specific dosage adjustment can be recommended for patients with renal impairment based on eGFR
  • Closely monitor patients with known renal function impairment

Hepatic impairment

  • Not studied
  • Metabolically stable; hepatic metabolism does not contribute to viltolarsen elimination

Dosing Considerations

Monitor for kidney toxicity during treatment

Assess before initiating

  • Serum cystatin C
  • Urine dipstick
  • Urine protein-to-creatinine ratio
  • Consider measuring GFR

Dosage Forms & Strengths

injection, solution

  • 250mg/5mL (50mg/mL) single-dose vial

Duchenne Muscular Dystrophy

Indicated for Duchenne muscular dystrophy (DMD) in patients with a confirmed DMD gene mutation that is amenable to exon 53 skipping

80 mg/kg IV qWeek

Dosage Modifications

Renal impairment

  • Not studied
  • Excreted mostly unchanged in urine; therefore, renal impairment may increase viltolarsen exposure
  • Owing to the effect of reduced skeletal muscle mass on creatinine measurements in DMD, no specific dosage adjustment can be recommended for patients with renal impairment based on eGFR
  • Closely monitor patients with known renal function impairment

Hepatic impairment

  • Not studied
  • Metabolically stable; hepatic metabolism does not contribute to viltolarsen elimination

Dosing Considerations

Monitor for kidney toxicity during treatment

Assess before initiating

  • Serum cystatin C
  • Urine dipstick
  • Urine protein-to-creatinine ratio
  • Consider measuring GFR
Next:

Adverse Effects

>10%

Upper respiratory tract infection (63%)

Injection site reaction (25%)

Cough (19%)

Pyrexia (19%)

Contusion (13%)

Arthralgia (13%)

Diarrhea (13%)

Vomiting (13%)

Abdominal pain (13%)

Ejection fraction decreased (13%)

Urticaria (13%)

Previous
Next:

Warnings

Contraindications

None

Cautions

Kidney toxicity

  • Kidney toxicity observed in animals
  • Clinical experience with viltolarsen is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides
  • Monitor kidney function during treatment
  • Serum creatinine may not reliably measure kidney function in patients with DMD owing to reduced skeletal muscle mass
  • Measure serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio before initiating
  • Consider measuring GFR using an exogenous filtration marker before initiating
  • During treatment, monitor urine dipstick every month and serum cystatin C and urine protein-to-creatinine ratio q3Months
  • If persistent increased serum cystatin C or proteinuria detected, refer to a pediatric nephrologist for further evaluation
Previous
Next:

Pregnancy & Lactation

Pregnancy

There are no human or animal data available

Lactation

There are no human or animal data to assess effect on milk production

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Antisense oligonucleotide of the phosphorodiamidate morpholino oligomer (PMO) subclass

Binds to exon 53 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping

Exon skipping is intended to allow for production of an internally truncated dystrophin protein

The underlying cause of DMD is a mutation or error in the gene for dystrophin, an essential protein involved in muscle fiber function

Absorption

Bioavailability: 100% (assumed)

Peak plasma time: 1 hr (end of infusion)

Distribution

Protein bound: 39-40%

Vd: 300 mL/kg

Metabolism

Metabolically stable; no metabolites detected in plasma or urine

Elimination

Half-life: 2.5 hr

Plasma clearance: 217 mL/hr/kg

Excretion: Mainly as unchanged drug in urine

Pharmacogenomics

~8% of patients with DMD have a mutation amenable to exon 53 skipping

Previous
Next:

Administration

IV Compatibilities

0.9% NaCl

IV Preparation

Inspect vial visually for particulate matter and discoloration before administration; solution should appear clear and colorless

Calculate dose and number vials required

Withdraw calculated dose from appropriate number of vials

If volume of viltolarsen dose <100 mL

  • Dilution in 0.9% NaCl required
  • Withdraw from 100-mL infusion bag volume of 0.9% NaCl equivalent to calculated volume of viltolarsen, THEN
  • Inject viltolarsen dosage volume into infusion bag to total a volume of 100 mL

If volume of viltolarsen dose ≥100 mL

  • Dilution is not required
  • Inject viltolarsen dosage volume into empty infusion bag

Visually inspect infusion bag for particulates

Gently invert bag to ensure equal distribution of product; do not shake

IV Administration

Administer by IV infusion using peripheral or central venous catheter over 1 hr

Flush IV line with 0.9% NaCl after infusion

Filtration not required

Do not mix with other medications or infuse other medications concomitantly via the same IV line

Missed dose: Administer as soon as possible after the scheduled dose time

Storage

Unopened vials

  • Refrigerate at 2-8ºC (36-46ºF)
  • Do not freeze

Diluted solution

  • Contains no preservatives
  • Room temperature: Infuse as soon as possible if stored at 20-26ºC (68-79ºF), but no more than 5 hr after preparation; complete infusion within 6 hr of preparation (allowing for 1 hr of infusion time)
  • Refrigerated: If not used immediately, may refrigerate for up to 24 hr at 2-8ºC (36-46ºF)
  • Do not freeze
Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.